HIV Drug Resistance and Low-level Viremia

Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases, Brigham and Woman’s Hospital
Professor of Medicine, Harvard Medical School, Cambridge, MA

CME VIDEOTop of page

Learning Objectives: Top of page

At the completion of this educational session, learners will:
  1. Know resistance patterns to newer antiretroviral drugs for the treatment and prevention of HIV disease.
  2. Understand implications of HIV drug resistance on the sequencing of antiretroviral agents in combination therapy.
  3. Appreciate the clinical significance of low-level viremia in HIV disease.

About the Presenter: Top of page

Dan Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection, chaired several multicenter studies of HIV therapy and is a member of the DHHS panel on guidelines for antiretroviral therapy. He has served on numerous NIH committees and editorial boards, and previously served as Chair of the HIV Medicine Association Board of Directors. He currently serves as Principal Investigator and Chair of the AIDS Clinical Trials Group, and as an Associate Editor of the Journal of Infectious Diseases. His research interests focus on antiretroviral therapy, drug resistance and HIV eradication.

How to get CME: Top of page

To obtain CME credit for this and other PRN programs, please visit the PRN Video Channel at the Clinical Education Initiative (CEI) web site PRN and the Medical Society of the State of New York (MSSNY) jointly sponsor PRN enduring materials for CME, and provide them at no cost to the AIDS Institute of the New York State Department of Health (NYSDOH) for broadcast through the CEI. We thank the NYSDOH for making our CME programs available to a wider audience, and hope you will also browse the many other educational opportunities offered by the CEI.

You must be logged in to post a comment. Login | Register